scholarly journals Inhibition of Human Liver Aldehyde Oxidase: Implications for Potential Drug-Drug Interactions

2011 ◽  
Vol 39 (12) ◽  
pp. 2381-2386 ◽  
Author(s):  
John T. Barr ◽  
Jeffrey P. Jones
Keyword(s):  
Drug Interactions ◽  
Human Liver ◽  
Aldehyde Oxidase ◽  
Potential Drug

OTC Orlistat Poses Potential Drug Interactions

2006 ◽  
Vol 36 (4) ◽  
pp. 8
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Drug Interactions ◽  
Potential Drug

Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase

Xenobiotica ◽  
1996 ◽  
Vol 26 (1) ◽  
pp. 1035-1055 ◽  
Author(s):  
A. A. Acheampong ◽  
D-S. Chien ◽  
S. Lam ◽  
S. Vekich ◽  
A. Breau ◽  
...  
Keyword(s):  
Human Liver ◽  
Aldehyde Oxidase ◽  
Rabbit Liver

scholarly journals A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma

2021 ◽  
pp. 107815522110313
Author(s):  
Emre Demir ◽  
Osman Sütcüoğlu ◽  
Beril Demir ◽  
Oktay Ünsal ◽  
Ozan Yazıcı
Keyword(s):  
Drug Interactions ◽  
Toxic Hepatitis ◽  
Antiviral Agents ◽  
Antiviral Agent ◽  
Aldehyde Oxidase ◽  
Chemotherapeutic Agents ◽  
High Dose ◽  
Drug Induced ◽  
Metastatic Osteosarcoma ◽  
Grade 3

Introduction Favipiravir is an antiviral agent that is recently used for SARS-CoV2 infection. The drug-drug interactions of favipiravir especially with chemotherapeutic agents in a patient with malignancy are not well known. Case report The patient diagnosed with metastatic osteosarcoma was given high dose methotrexate treatment, and favipiravir was started on the third day of the treatment with suspicion of SARS-CoV2 infection. Grade 3 hepatotoxicity developed after favipiravir. Management & outcome: The acute viral hepatitis panel and autoimmune liver disease panel were negative. The ultrasound of the abdomen was unremarkable for any hepatobiliary pathology. The all viral and hepatobiliary possible etiological factors were ruled out. The patient’s liver enzymes increased just after (12 hours later) the initiation of favipiravir, and we diagnosed toxic hepatitis caused by favipiravir-methotrexate interaction. Therefore, methylprednisolone 1 mg/kg dose was started for a presumed diagnosis of toxic hepatitis. Hepatotoxicity completely regressed after favipiravir was discontinued. Discussion Favipiravir may inhibit methotrexate elimination by inhibiting aldehyde oxidase and its sequential use may cause hepatotoxicity in this case. The clinicians should keep in mind possible drug interactions while using new antiviral agents against SARS-CoV2 like favipiravir.

Sign in / Sign up

Export Citation Format

Share Document